Affiliation:
1. Kuban State Medical University;
Scientific Research Institution — S.V. Ochapovsky Regional Clinic Hospital No. 1;
Bukhara State Medical Institute named after Abu Ali ibn Sino
2. Kuban State Medical University;
Scientific Research Institution — S.V. Ochapovsky Regional Clinic Hospital No. 1
3. Bukhara State Medical Institute named after Abu Ali ibn Sino
4. Scientific Research Institution — S.V. Ochapovsky Regional Clinic Hospital No. 1
Abstract
Purpose: to evaluate the efficacy and safety of preservative free travoprost generic in primary open-angle glaucoma patients. Patients and methods. 40 patients with compensated primary open-angle glaucoma (POG) and dry eye (DE) were examined: 1st group (20 patients) with the initial stage of POG (travoprost with a preservative monotherapy), 2nd group with an advanced stage of POG (travoprost with a preservative in combination therapy). In all patients, travoprost with a preservative was replaced with preservative free travoprost (Traviolan, 1 time per day, in the evening). Control: 1 — when included in the study; 2 — 4 weeks after replacing travoprost with a preservative for preservative free travoprost. Efficiency criteria: absence of negative dynamics of intraocular pressure (IOP) and MD and PSD perimetric indices (dB; Optos). Safety criteria: absence of OSDI (scores), tear film brake up time (TBUT; Norn’s test, s), lower tear meniscus height (LTMH, µm; OptoVue) and Bijsterveld’s xerosis index (XI, scores) negative dynamics. Results. At the 2nd control point, all observed did not have a statistically significant dynamics of IOP, MD, PSD. In patients of both groups, at the 2nd control point, there was the OSDI and TBUT statistically significant positive dynamics, and in patients of the 1st group — XI statistically significant positive dynamics. The trend towards to XI decreasing in 2nd group patients and the LTMH dynamics in both groups turned out to be statistically insignificant. Conclusion. Preservative free travoprost has shown efficacy comparable to that of travoprost with preservative in both monotherapy and combination therapy. Significant positive dynamics of OSDI and TBUT in patients of both groups and XI in 1st group patients after switching to preservative free travoprost indicates a good “safety profile” of therapy in terms of its effect on the ocular surface state in DE conditions, which, from our point of view, may contribute to maintaining the “quality of life” and patients compliance.
Publisher
PE Polunina Elizareta Gennadievna
Reference29 articles.
1. National guidelines for glaucoma for practitioners. Ed. 4th, corrected and supplemented. Edited by Egorov E.A, Erichev V.P. Moscow: GEOTAR-Media, 2019. 383 p. (In Russ.).
2. Medical Treatment of Glaucoma. WGA Consensus Series. 7. Eds. Weinreb R., Makoto A., Susanna R., Goldberg I., Migdal C., Liebmann J. Kugler Publications, 2010. 309 p.
3. Terminology and guidelines for glaucoma. 5th edition. EGS, 2020. 168 p.
4. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005 Jun;112(6):953–961. doi: 10.1016/j.ophtha.2004.12.035.
5. Erb C. Glaucoma and Dry Eye. Bremen: UNI-MED Verlag AG, 2012. 102 p.